Skip to main content
Premium Trial:

Request an Annual Quote

Decode Shares Tumble 14 Percent After Company Halts Heart Drug Study

NEW YORK (GenomeWeb News) — Shares in Decode Genetics were down 14.19 percent, or $.82, at $5.02 in mid-afternoon trading after the company said it was forced to halt the study of a heart drug.
 
Decode said it suspended the Pjhase III trial of its heart attack drug DG031 after discovering that tablets appear to dissolve more slowly over time than had been originally believed.
 
That prompted concerns that the tablets would release too little drug, limiting the effect of the compound and “undermin[e] the trial’s chances of success,” Decode said in a statement.
 
Decode said it has told the US Food and Drug Administration of the situation and is exploring alternative manufacturing processes.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.